GlobeImmune is developing Tarmogen product candidates to treat cancer and infectious diseases.

Tarmogens activate the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens target the molecular profile that distinguishes a diseased cell from a normal cell, and are designed to target specific antigens that play a role in oncology indications and infectious diseases. READ MORE »

Fact Sheet

Learn about our Tarmogen® platform, our leading oncology and infectious disease product candidates and our GlobeImmune management team.

Recent News